Bioxytran Inc BIXT

Healthcare Biotechnology

Bioxytran, Inc. is a clinical-stage pharmaceutical company. The Company is focused on the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans. The Company's lead drug candidate, code named BXT-25, is an oxygen-carrying small molecule consisting of bovine hemoglobin stabilized with a co-polymer with an intended application, which includes the treatment of hypoxic conditions in the brain resulting from stroke. The Company, through its subsidiary, Pharmalectin Inc., is focused on the development, manufacturing, and commercialization of therapeutic drugs designed to address viral diseases in humans. Pharmalectin Inc. has developed a method designed to reduce the viral load and modulate the immune system using a galectin inhibitor. Its lead drug candidate, named ProLectin-Rx, is a complex polysaccharide derived from pectin that binds to, and blocks the activity of galectin-1, a type of galectin.

OTCQB:BIXT - Post by User

Bioxytran Inc

<< Previous

Bullboard Posts

Next >>

Post by amritadaniqueon Oct 19, 2023 7:31am

86 Views

Post# 35690403

$BIXT: Pioneering Growth and Innovation in Biotech

Bioxytran, Inc. ($BIXT) stands as a compelling presence in the biotech industry with remarkable statistics. Their market capitalization, exceeding $24 million, combined with 144 million+ outstanding shares, paints a picture of potential for growth and innovation. A strong 30-day average volume of 174,419 indicates a rising interest in their pharmaceutical solutions. Bioxytran, Inc. is poised for a promising future in medical science.

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario